Diet-Regulating Microbiota and Host Immune System in Liver Disease

Eom, Jung A; Kwon, Goo Hyun; Kim, Na Yeon; Park, Eun Ju; Won, Sung Min; Jeong, Jin Ju; Ganesan, Raja; Gupta, Haripriya; Gebru, Yoseph Asmelash; Sharma, Satyapriya; Choi, Ye Rin; Kim, Hyeong Seop; Yoon, Sang Jun; Hyun, Ji Ye; Jeong, Min Kyo; Park, Hyojin; Min, Byeong Hyun; Choi, Mi Ran; Kim, Dong Joon; Suk, Ki Tae

doi:10.3390/ijms22126326

Cited by 10 publications

(6 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GM has been widely studied to be part of the pathophysiology of many diseases 88 . Among these are inflammatory bowel disease (IBD), 89 Microglial function, 90 food allergy, 91 obesity, 92 Parkinson's disease (PD), 93 chronic liver disease, 94 and IBD psoriasis 95 . DNA methylation of epigenetic mechanisms and alteration of the GM are paralleling with IBD 96 .…”

Section: Discussionmentioning

confidence: 99%

The connection between epigenetics and gut microbiota‐current perspective

Yuan,

Tan,

Bajinka

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

Both the epigenetic changes and gut microbiota (GM) have attracted a growing interest in establishing effective diagnostics and potential therapeutic strategies for a number of diseases. These disorders include metabolic, central nervous system‐related diseases, autoimmune, and gastrointestinal infections (GI). Despite the number of studies, there is no extensive review that connects the epigenetics modifications and GM as biomarkers that could confer effective diagnostics and confer treatment options. To this end, this review hopes to give detailed information on connecting the modifications in epigenetic and GM. An updated and detailed information on the connection between the epigenetics factors and GM that influence diseases are given. In addition, the review showed some associations between the epigenetics to the maternal GM and offspring health. Finally, the limitations of the concept and prospects into this new emerging discipline were also looked into. Although this review elucidated on the maternal diet and response to offspring health with respect to GM and epigenetic modifications, there still exist various limitations to this newly emerging discipline. In addition to integrating complementary multi‐omics data, longitudinal sampling will aid with the identification of functional mechanisms that may serve as therapeutic targets. To this end, this review gave a detailed perspective into harnessing disease diagnostics, prevention and treatment options through epigenetics and GM.

show abstract

Section: Discussionmentioning

confidence: 99%

The connection between epigenetics and gut microbiota‐current perspective

Yuan,

Tan,

Bajinka

et al. 2024

Cell Biochemistry & Function

View full text Add to dashboard Cite

show abstract

“…Using advanced computational techniques and prosperous study designs, gut microbiome analysis combined with other clinical and diagnostic examinations represents a future standard for predicting disease sensitivity, defining CLD status, and providing personalized treatment through supplements, diet, and medication [ 160 , 228 ].…”

Section: Unknowns and Future Goals Of Microbiome Research In Cldmentioning

confidence: 99%

The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

Stojic,

Kukla,

Grgurevic

2023

Diagnostics

View full text Add to dashboard Cite

Chronic liver disease (CLD) is a significant global health burden, leading to millions of deaths annually. The gut–liver axis plays a pivotal role in this context, allowing the transport of gut-derived products directly to the liver, as well as biological compounds from the liver to the intestine. The gut microbiota plays a significant role in maintaining the health of the digestive system. A change in gut microbiome composition as seen in dysbiosis is associated with immune dysregulation, altered energy and gut hormone regulation, and increased intestinal permeability, contributing to inflammatory mechanisms and damage to the liver, irrespective of the underlying etiology of CLD. The aim of this review is to present the current knowledge about the composition of the intestinal microbiome in healthy individuals and those with CLD, including the factors that affect this composition, the impact of the altered microbiome on the liver, and the mechanisms by which it occurs. Furthermore, this review analyzes the effects of gut microbiome modulation on the course of CLD, by using pharmacotherapy, nutrition, fecal microbiota transplantation, supplements, and probiotics. This review opens avenues for the translation of knowledge about gut–liver interplay into clinical practice as an additional tool to fight CLD and its complications.

show abstract

“…The physiological process of gluconeogenesis, AMPK activity, and insulin sensitivity in the liver are significantly affected ( 52 , 55 ). Finally, SCFAs are a significant signaling metabolome and are used for communication between host tissues and microbiota through the gut-brain-liver axis ( 56 , 57 ).…”

Section: Gut Microbiota and Short Chain Fatty Acidsmentioning

confidence: 99%

“…The gut microbiota plays an ameliorative role in liver diseases. Liver diseases such as fatty liver, hepatitis, and cirrhosis are related to bile acid secretion disorder and metabolic syndrome ( 56 , 86 , 87 ). Table 3 lists the more important metabolites in the human gut microbiome.…”

Section: Gut Microbiota and One Carbon Metabolismsmentioning

confidence: 99%

Recent Trends of Microbiota-Based Microbial Metabolites Metabolism in Liver Disease

et al. 2022

Self Cite

View full text Add to dashboard Cite

The gut microbiome and microbial metabolomic influences on liver diseases and their diagnosis, prognosis, and treatment are still controversial. Research studies have provocatively claimed that the gut microbiome, metabolomics understanding, and microbial metabolite screening are key approaches to understanding liver cancer and liver diseases. An advance of logical innovations in metabolomics profiling, the metabolome inclusion, challenges, and the reproducibility of the investigations at every stage are devoted to this domain to link the common molecules across multiple liver diseases, such as fatty liver, hepatitis, and cirrhosis. These molecules are not immediately recognizable because of the huge underlying and synthetic variety present inside the liver cellular metabolome. This review focuses on microenvironmental metabolic stimuli in the gut-liver axis. Microbial small-molecule profiling (i.e., semiquantitative monitoring, metabolic discrimination, target profiling, and untargeted profiling) in biological fluids has been incompletely addressed. Here, we have reviewed the differential expression of the metabolome of short-chain fatty acids (SCFAs), tryptophan, one-carbon metabolism and bile acid, and the gut microbiota effects are summarized and discussed. We further present proof-of-evidence for gut microbiota-based metabolomics that manipulates the host's gut or liver microbes, mechanosensitive metabolite reactions and potential metabolic pathways. We conclude with a forward-looking perspective on future attention to the “dark matter” of the gut microbiota and microbial metabolomics.

show abstract

Diet-Regulating Microbiota and Host Immune System in Liver Disease

Cited by 10 publications

References 110 publications

The connection between epigenetics and gut microbiota‐current perspective

The connection between epigenetics and gut microbiota‐current perspective

The Intestinal Microbiota in the Development of Chronic Liver Disease: Current Status

Recent Trends of Microbiota-Based Microbial Metabolites Metabolism in Liver Disease

Contact Info

Product

Resources

About